Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma

CompletedOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

October 12, 2022

Study Completion Date

May 5, 2024

Conditions
Churg-Strauss SyndromeEosinophilic AsthmaEosinophilic EsophagitisEosinophilic Pneumonia
Interventions
DIAGNOSTIC_TEST

Autoantibody ELISA

Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.

DIAGNOSTIC_TEST

Granulocyte Immunofluorescence

The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.

Trial Locations (2)

E1 4DG

Barts Health NHS Trust, Dept of Rheumatology, Mile End Hospital, London

EC1A 7BE

Barts Health NHS Trust, Dept of Respiratory Medicine, St Bartholomew's Hospital, London

All Listed Sponsors
lead

Queen Mary University of London

OTHER

NCT04671446 - Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma | Biotech Hunter | Biotech Hunter